<b>Conclusions:</b> High <i>TFRC</i> expression, therefore, indicates worse clinical risk across multiple common tumor types but potentially increased susceptibility to cytotoxic immune effectors, informing the development of TFR1 biomarker-driven therapeutic strategies. Here, TFRC is linked to neoplasm.